Medicare began covering weight-loss drugs for seniors this week. For patients long shut out from the GLP-1 boom, the opening is a real milestone. For Wall Street, it isn't the immediate windfall the headlines suggest.
Drugs such as Wegovy and Zepbound have rocketed into the national spotlight and have been used by millions of Americans. But federal law bars Medicare from paying for medications used for weight control. As a result, many seniors unable to afford the pricey drugs have been left behind.
For Eli Lilly and Novo Nordisk, the makers of Zepbound and Wegovy, Medicare was always a big prize: the nation's largest pool of drug demand, and the one big market obesity treatment couldn't reach. But for now the payoff to them will be slow and hard to bank on.
Start with who actually qualifies. By some estimates, as many as 20 million U.S. seniors are overweight or obese. But the pool that might gain access through Medicare's new pathway, known as Bridge, is far smaller. The program, which lets eligible seniors get the drugs for a $50 monthly copay, is temporary, and its rules are tighter than the drugs' Food and Drug Administration approvals, requiring a higher weight threshold or a serious related condition. Anyone already receiving GLP-1 coverage through standard Medicare drug benefits, for diabetes, sleep apnea or related conditions, is excluded and stays on their existing plan.
Run those filters, and the number looks modest. KFF, a nonpartisan health-research group, mapped Medicare claims and estimated 3.8 million seniors eligible, out of more than 13 million who are overweight or obese. The agency agrees: Its Medicare director, Chris Klomp, said the program would start in the "single-digit millions."
The revenue math follows from there. Evan Seigerman, an analyst at BMO Capital Markets, pegs the near-term opportunity at roughly $3 billion a year in added sales, assuming modest uptake. Push participation up, and the figure could be higher. Those numbers aren't trivial, but it takes a lot to make a significant difference for two companies whose combined annual GLP-1 sales are running north of $80 billion.
And even the modest case assumes a clean rollout, something new government programs rarely deliver. Doctors must attest that patients meet strict criteria. Pharmacies must route claims through unfamiliar channels. As Scott Kahan, director of the National Center for Weight and Wellness, puts it, expect confusion and hiccups at the outset.
Then comes the part that is harder to predict long-term. The program exists only because the government designed it as a temporary workaround to a law that still bars Medicare from covering weight loss. It was meant to be brief, a six-month on-ramp to a permanent, insurer-run benefit through Medicare's Part D drug plans, called Balance.
But the plan to hand it off for 2027 fell apart. Too few private plans agreed to take on the cost, and in April the government shelved Balance indefinitely, extending the intended timeline for Bridge instead and continuing to foot the bill itself through 2027. Insurers could still step in for 2028, but nothing compels them to, and they balked once for a simple reason: Covering this category pushes premiums higher for everyone.
Unless that math changes, Kahan said, this risks becoming a bridge to nowhere. What could rescue it, he said, is proof the drugs ultimately pay for themselves through better health and lower downstream costs, the kind of evidence the program might help surface.
Longer term, the opportunity could grow into something meaningful, Seigerman said, and if uptake outruns expectations, there is real upside. But that same uncertainty cuts the other way. It is hard to build a clean model around a policy that could quietly become permanent, or disappear in its current form.
None of which means investors shouldn't pay attention. The program is a crucial door opening while some are quietly closing. Commercial coverage of these drugs for obesity, a major engine of their growth, has begun to retreat. More than a quarter of big companies say they are adding criteria this year or next, while many others are planning to drop coverage for weight-loss purposes altogether.
In other words, Bridge represents modest revenue today, but government support could become crucial for weight-loss drug providers and patients.
For Wall Street, which runs on numbers it can model, this is a variable to watch, not yet one to bank on.
Write to David Wainer at david.wainer@wsj.com
(END) Dow Jones Newswires
July 02, 2026 05:30 ET (09:30 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments